Endocrine Abstracts

Effective treatments of malignant pheochromocytoma have not been established. Although 131-I-MIBG radiotherapy, chemotherapy with a combination of cyclophosphamide, vincristine and dacarbazine (CVD), and molecular target therapies have been used for unresectable tumors, those are usually palliative and rarely curative. However, excessive catecholamine impairs the activities of daily living by causing various symptoms (e.g. palpitation, paroxysmal hypertension and hypotension a...

Objective: Osteoporosis and osteopenia (OS/OP) are frequent in patients with cortisol-producing adrenal adenomas (CPA) associated with severity of cortisol excess (CE). However, the relationship between OS/OP and CE severity considering sex differences is unknown.Patients and Methods: This was a retrospective cross-sectional observational study conducted as a part of the Advancing Care and Pathogenesis of Intractable Adrenal Disease in Japan (ACPA-J) stu...

Introduction: Pheochromocytoma and paraganglioma (PPGL) are rare endocrine tumors with few effective treatment options for malignant cases. Novel therapeutic indications, such as 177Lu-DOTA-TATE and immune checkpoint inhibitors (ICIs) for patients with PPGL, have been investigated in several clinical trials. Emerging evidence shows that somatostatin receptor 2 (SSTR2) in other cancer types correlates with the tumor microenvironment (TME) activation and could be a predictive bi...

Primary aldosteronism (PA) is the most major cause of secondary hypertension, with its prevalence ranging from 3 to 20% of the hypertensive patients. Although guideline for diagnosis of PA has been established by the Endocrine Society, details of its applicability remain to be elucidated. In this study, we investigated the applicability of each step of the guideline in hypertensive patients by the multi-center collaborative study of National Hospital Organization (NHO) in Japa...